facebook page
Follow Me on Pinterest
twitter page
google plus page
rss feed

Recalled Product

Item detail and remedy information

Search Recalls or Browse by Category
Consumer Products (?)
Food & Health (?)
Vehicles (?)
Home > Recalled Products > Drugs > Elevated Impurity > ScieGen Pharmaceuticals, Inc Irbesartan Tablets, USP 75 Mg, 150 Mg, And 300 Mg Dosage Forms

Recall: ScieGen Pharmaceuticals, Inc Irbesartan Tablets, USP 75 Mg, 150 Mg, And 300 Mg Dosage Forms


On 2018-10-26, the FDA announced that Aurobindo Pharma Limited is conducting a recall on Irbesartan Tablets, USP 75 Mg, 150 Mg, And 300 Mg Dosage Forms due to a possible n-nitrosodiethylamine (ndea). The recalled products were sold under the brand name(s) ScieGen Pharmaceuticals and Inc during an unspecified time period throughout the regions shown in the map below.

In recent months, there have been 4 drugs recalls due to potential elevated impurity, including valsartan/amlodipine/hctz, valsartan/amlodipine and valsartan tablets, valsartan/amlodipine/hctz tablets and more. Additionally, there have been 23 drug and medical device recalls due to other health hazards as well as 77 food recalls.

Email Me About Recalls On:
Food  |  Drugs  |  Medical Devices  |  Pet Care Products  |  All of These

Aurobindo Pharma Limited, Logo
Note: Images may not be available for every version. Please review the detailed description below.

Company Contact Information:

Name: Aurobindo Pharma Limited
Phone: 732-839-4380

Do you work for a company involved with this recall? Contact us to learn how you can control data, information and ads shown on this page.

Detailed Recall Information

Regions Where Sold: Because the region was not specified, it is assumed that this product was available nationwide.

Product Description: Irbesartan Tablets, USP 75 mg, 150 mg, and 300 mg dosage forms

Brand Name(s): ScieGen Pharmaceuticals, Inc

Reason for Recall: Elevated Impurity of N-nitrosodiethylamine (NDEA)

Official Recall Date: 2018-10-26


Additional information provided by the

Aurobindo Pharma Limited is voluntarily recalling 22 Batches of the drug substance Irbesartan due to the presence of an impurity, N-nitrosodiethylamine (NDEA). The impurity, which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC). Read More.

More information may be available at

Latest Safety Recalls

Select image for details, including additional styles.




Do you have comments or questions about this recall? Share them here.
Note: The recalling companies may not be monitoring these comments; they should be directed toward the public. Community Guidelines apply.
comments powered by Disqus
Back to Top

Sources may include Food & Drug Administration (FDA), United States Department of Agriculture (USDA), Health Canada and companies involved with this or a related recall.

Search Recalled Products or Browse by Category
Consumer Products (?)
Food & Health (?)
Vehicles (?)
Latest Product Recalls
Register Products
Check for Recalls
Find Resources
Brands & Retailers
Connect to Customers

Consignment Sales
Check Inventory
Install Recall Finder
Take Safety Pledge

Home Inspectors
Check Appliances
APIs & Feeds
Recall Search for Web
Recall Search for Mobile
Facebook Apps

Product Recall Statistics